Insulin-degrading enzyme: new therapeutic target for diabetes and Alzheimer's disease? - PubMed (original) (raw)

Review

. 2016 Dec;48(8):614-624.

doi: 10.1080/07853890.2016.1197416. Epub 2016 Jun 19.

Affiliations

• PMID: 27320287
• DOI: 10.1080/07853890.2016.1197416

Free article

Review

Insulin-degrading enzyme: new therapeutic target for diabetes and Alzheimer's disease?

Olga Pivovarova et al. Ann Med. 2016 Dec.

Free article

Abstract

Insulin-degrading enzyme (IDE) is a major enzyme responsible for insulin degradation. In addition to insulin, IDE degrades many targets including glucagon, atrial natriuretic peptide, and beta-amyloid peptide, regulates proteasomal degradation and other cell functions. IDE represents a pathophysiological link between type 2 diabetes (T2DM) and late onset Alzheimer's disease (AD). Potent and selective modulators of IDE activity are potential drugs for therapies of both diseases. Acute treatment with a novel IDE inhibitor was recently tested in a mouse study as a therapeutic approach for the treatment of T2DM. In contrast, effective IDE activators can be used for the AD treatment. However, because of the pleiotropic IDE action, the sustained treatment with systemic IDE modulators should be carefully tested in animal studies. Development of substrate-selective IDE modulators could overcome possible adverse effects of IDE modulators associated with multiplicity of IDE targets. KEY MESSAGES Insulin-degrading enzyme (IDE) represents a pathophysiological link between type 2 diabetes (T2DM) and Alzheimer's disease (AD). Selective modulators of IDE activity are potential drugs for both T2DM and AD treatment. Development of substrate-selective IDE modulators could overcome possible adverse effects of IDE modulators associated with multiplicity of IDE targets.

Keywords: Alzheimer’s disease; insulin-degrading enzyme; type 2 diabetes.

PubMed Disclaimer

Similar articles

• Targeting Insulin-Degrading Enzyme to Treat Type 2 Diabetes Mellitus.
  Tang WJ. Tang WJ. Trends Endocrinol Metab. 2016 Jan;27(1):24-34. doi: 10.1016/j.tem.2015.11.003. Epub 2015 Dec 2. Trends Endocrinol Metab. 2016. PMID: 26651592 Free PMC article. Review.
• Insulin, insulin-degrading enzyme and amyloid-beta peptide in Alzheimer's disease: review and hypothesis.
  Qiu WQ, Folstein MF. Qiu WQ, et al. Neurobiol Aging. 2006 Feb;27(2):190-8. doi: 10.1016/j.neurobiolaging.2005.01.004. Epub 2005 Feb 17. Neurobiol Aging. 2006. PMID: 16399206 Review.
• Insulin-degrading enzyme: a link between Alzheimer's and type 2 diabetes mellitus.
  Haque R, Nazir A. Haque R, et al. CNS Neurol Disord Drug Targets. 2014 Mar;13(2):259-64. doi: 10.2174/18715273113126660139. CNS Neurol Disord Drug Targets. 2014. PMID: 24059320 Review.
• Insulin degrading enzyme contributes to the pathology in a mixed model of Type 2 diabetes and Alzheimer's disease: possible mechanisms of IDE in T2D and AD.
  Li H, Wu J, Zhu L, Sha L, Yang S, Wei J, Ji L, Tang X, Mao K, Cao L, Wei N, Xie W, Yang Z. Li H, et al. Biosci Rep. 2018 Jan 10;38(1):BSR20170862. doi: 10.1042/BSR20170862. Print 2018 Feb 28. Biosci Rep. 2018. PMID: 29222348 Free PMC article.
• New Insights on the Regulation of the Insulin-Degrading Enzyme: Role of microRNAs and RBPs.
  Martín-Martín Y, Pérez-García A, Torrecilla-Parra M, Fernández-de Frutos M, Pardo-Marqués V, Casarejos MJ, Busto R, Ramírez CM. Martín-Martín Y, et al. Cells. 2022 Aug 16;11(16):2538. doi: 10.3390/cells11162538. Cells. 2022. PMID: 36010613 Free PMC article.

Cited by

• Advances in Anti-Diabetic Cognitive Dysfunction Effect of Erigeron Breviscapus (Vaniot) Hand-Mazz.
  Gu S, Zhou Z, Zhang S, Cai Y. Gu S, et al. Pharmaceuticals (Basel). 2022 Dec 29;16(1):50. doi: 10.3390/ph16010050. Pharmaceuticals (Basel). 2022. PMID: 36678547 Free PMC article. Review.
• Possible Role of Insulin-Degrading Enzyme in the Physiopathology of Retinitis Pigmentosa.
  Sánchez-Cruz A, Hernández-Fuentes MD, Murillo-Gómez C, de la Rosa EJ, Hernández-Sánchez C. Sánchez-Cruz A, et al. Cells. 2022 May 12;11(10):1621. doi: 10.3390/cells11101621. Cells. 2022. PMID: 35626658 Free PMC article.
• Monoclonal Antibody Therapy in Alzheimer's Disease.
  Neațu M, Covaliu A, Ioniță I, Jugurt A, Davidescu EI, Popescu BO. Neațu M, et al. Pharmaceutics. 2023 Dec 29;16(1):60. doi: 10.3390/pharmaceutics16010060. Pharmaceutics. 2023. PMID: 38258071 Free PMC article. Review.
• Neuroprotective Effect of Carnosine Is Mediated by Insulin-Degrading Enzyme.
  Distefano A, Caruso G, Oliveri V, Bellia F, Sbardella D, Zingale GA, Caraci F, Grasso G. Distefano A, et al. ACS Chem Neurosci. 2022 May 18;13(10):1588-1593. doi: 10.1021/acschemneuro.2c00201. Epub 2022 Apr 26. ACS Chem Neurosci. 2022. PMID: 35471926 Free PMC article.
• Type 2 diabetes sex-specific effects associated with E167K coding variant in TM6SF2.
  Fan Y, Wolford BN, Lu H, Liang W, Sun J, Zhou W, Rom O, Mahajan A, Surakka I, Graham SE, Liu Z, Kim H, Ramdas S, Fritsche LG, Nielsen JB, Gabrielsen ME, Hveem K, Yang D, Song J, Garcia-Barrio MT, Zhang J, Liu W, Zhang K, Willer CJ, Chen YE. Fan Y, et al. iScience. 2021 Oct 2;24(11):103196. doi: 10.1016/j.isci.2021.103196. eCollection 2021 Nov 19. iScience. 2021. PMID: 34746691 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Atypon

• Other Literature Sources

  • scite Smart Citations

• Medical

  • MedlinePlus Health Information